CDC Recommendations for Hepatitis C Screening Among Adults-United States, 2020, 23519 [2020-08960]
Download as PDF
<![CDATA[
Federal Register / Vol. 85, No. 82 / Tuesday, April 28, 2020 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Docket No. CDC–2019–0094]
CDC Recommendations for Hepatitis C
Screening Among Adults—United
States, 2020
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of availability.
AGENCY:
The Centers for Disease
Control and Prevention (CDC)
announces the availability of the final
CDC Recommendations for Hepatitis C
Screening Among Adults—United
States, 2020.
DATES: The final document was
published as an MMWR Reports &
Recommendations on April 10, 2020.
ADDRESSES: The document may be
found in the docket at
www.regulations.gov, Docket No. CDC–
2019–0084 and at https://www.cdc.gov/
mmwr/volumes/69/rr/rr6902a1.htm?s_
cid=rr6902a1_w.
FOR FURTHER INFORMATION CONTACT: CDR
Sarah Schillie, MD, MPH, MBA, Centers
for Disease Control and Prevention,
1600 Clifton Rd., NE U12–3, Atlanta,
GA 30329. Telephone: (404) 639–8000;
email: DVHpolicy@cdc.gov.
SUPPLEMENTARY INFORMATION: In 2019,
CDC determined that CDC
Recommendations for Hepatitis C
Screening Among Adults—United
States, 2020 constituted influential
scientific information (ISI) that will
have a clear and substantial impact on
important public policies and private
sector decisions. Under the Information
Quality Act, Public Law 106–554,
agencies are required to conduct peer
review of the information by specialists
in the field who were not involved in
the development of these
recommendations. CDC solicited
nominations for reviewers from the
American Association for the Study of
Liver Diseases (AASLD), Infectious
Diseases Society of America (IDSA) and
the American College of Obstetricians
and Gynecologists (ACOG). Six
clinicians with expertise in hepatology,
gastroenterology, internal medicine,
infectious diseases and/or obstetrics and
gynecology provided structured peer
reviews. Peer reviewers were supportive
of the recommendations and raised
comments about the benefit of screening
pregnant women and inclusion of a
prevalence threshold. Feedback
obtained during the peer review process
jbell on DSKJLSW7X2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
18:43 Apr 27, 2020
Jkt 250001
was carefully reviewed and considered
by CDC. Ultimately no changes to the
recommendation statement were made;
however, additional references and
justification for the recommendation to
screen during every pregnancy and
maintaining the prevalence threshold
were added to the document. A
summary of the peer review comments,
CDC’s response, and changes made to
the document in response to the
comments can be found in the
Supporting Materials tab of the docket
and at https://www.cdc.gov/hepatitis/
policy/isireview/PeerReviewCR.htm.
In addition, on October 28, 2019, CDC
published a notice in the Federal
Register (84 FR 57733) announcing the
opening of a docket to obtain public
comment on the draft recommendations
for hepatitis C screening among adults.
The comment period closed December
27, 2019. CDC received response from
69 commenters on the draft
recommendations document. Public
commenters included those from
academia, professional organizations,
industry, and the public.
Many of the comments from the
public were in support of the
recommendations. For those comments
that proposed changes, the majority
related to removing the
recommendation to screen for hepatitis
C in every pregnancy or removing the
prevalence threshold for universal
screening. Feedback obtained during
both the peer review process and the
public comment period was carefully
reviewed and considered by CDC.
Ultimately no changes to the
recommendation statement were made;
however, additional references and
justification for the recommendation to
screen during every pregnancy and
maintaining the prevalence threshold
were added to the document. A
summary of public comments and
CDC’s response is found in the
Supporting Materials tab of the docket.
Dated: April 23, 2020.
Sandra Cashman,
Executive Secretary, Centers for Disease
Control and Prevention.
[FR Doc. 2020–08960 Filed 4–27–20; 8:45 am]
BILLING CODE 4163–18–P
PO 00000
Frm 00019
Fmt 4703
Sfmt 4703
23519
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[CMS–3396–PN]
Medicare Program; Application From
National Association of Boards of
Pharmacy for Initial CMS-Approval of
Its Home Infusion Therapy
Accreditation Program
Centers for Medicare and
Medicaid Services, HHS.
ACTION: Notice with comment period.
AGENCY:
This proposed notice
acknowledges the receipt of an
application from National Association
of Boards of Pharmacy for initial
recognition as a national accrediting
organization for suppliers of home
infusion therapy services that wish to
participate in the Medicare program.
The statute requires that within 60 days
of receipt of an organization’s complete
application, the Centers for Medicare &
Medicaid Services (CMS) publishes a
notice that identifies the national
accrediting body making the request,
describes the nature of the request, and
provides at least a 30-day public
comment period.
DATES: To be assured consideration,
comments must be received at one of
the addresses provided below, no later
than 5 p.m. on June 26, 2020.
ADDRESSES: In commenting, please refer
to file code CMS–3396–PN.
Comments, including mass comment
submissions, must be submitted in one
of the following three ways (please
choose only one of the ways listed):
1. Electronically. You may submit
electronic comments on this regulation
to https://www.regulations.gov. Follow
the ‘‘Submit a comment’’ instructions.
2. By regular mail. You may mail
written comments to the following
address ONLY: Centers for Medicare &
Medicaid Services, Department of
Health and Human Services, Attention:
CMS–3396–PN, P.O. Box 8016,
Baltimore, MD 21244–8010.
Please allow sufficient time for mailed
comments to be received before the
close of the comment period.
3. By express or overnight mail. You
may send written comments to the
following address ONLY: Centers for
Medicare & Medicaid Services,
Department of Health and Human
Services, Attention: CMS–3396–PN,
Mail Stop C4–26–05, 7500 Security
Boulevard, Baltimore, MD 21244–1850.
For information on viewing public
comments, see the beginning of the
SUPPLEMENTARY INFORMATION section.
SUMMARY:
E:\FR\FM\28APN1.SGM
28APN1
]]>Agencies
[Federal Register Volume 85, Number 82 (Tuesday, April 28, 2020)]
[Notices]
[Page 23519]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-08960]
[[Page 23519]]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[Docket No. CDC-2019-0094]
CDC Recommendations for Hepatitis C Screening Among Adults--
United States, 2020
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice of availability.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention (CDC) announces
the availability of the final CDC Recommendations for Hepatitis C
Screening Among Adults--United States, 2020.
DATES: The final document was published as an MMWR Reports &
Recommendations on April 10, 2020.
ADDRESSES: The document may be found in the docket at
www.regulations.gov, Docket No. CDC-2019-0084 and at https://www.cdc.gov/mmwr/volumes/69/rr/rr6902a1.htm?s_cid=rr6902a1_w.
FOR FURTHER INFORMATION CONTACT: CDR Sarah Schillie, MD, MPH, MBA,
Centers for Disease Control and Prevention, 1600 Clifton Rd., NE U12-3,
Atlanta, GA 30329. Telephone: (404) 639-8000; email: [email protected].
SUPPLEMENTARY INFORMATION: In 2019, CDC determined that CDC
Recommendations for Hepatitis C Screening Among Adults--United States,
2020 constituted influential scientific information (ISI) that will
have a clear and substantial impact on important public policies and
private sector decisions. Under the Information Quality Act, Public Law
106-554, agencies are required to conduct peer review of the
information by specialists in the field who were not involved in the
development of these recommendations. CDC solicited nominations for
reviewers from the American Association for the Study of Liver Diseases
(AASLD), Infectious Diseases Society of America (IDSA) and the American
College of Obstetricians and Gynecologists (ACOG). Six clinicians with
expertise in hepatology, gastroenterology, internal medicine,
infectious diseases and/or obstetrics and gynecology provided
structured peer reviews. Peer reviewers were supportive of the
recommendations and raised comments about the benefit of screening
pregnant women and inclusion of a prevalence threshold. Feedback
obtained during the peer review process was carefully reviewed and
considered by CDC. Ultimately no changes to the recommendation
statement were made; however, additional references and justification
for the recommendation to screen during every pregnancy and maintaining
the prevalence threshold were added to the document. A summary of the
peer review comments, CDC's response, and changes made to the document
in response to the comments can be found in the Supporting Materials
tab of the docket and at https://www.cdc.gov/hepatitis/policy/isireview/PeerReviewCR.htm.
In addition, on October 28, 2019, CDC published a notice in the
Federal Register (84 FR 57733) announcing the opening of a docket to
obtain public comment on the draft recommendations for hepatitis C
screening among adults. The comment period closed December 27, 2019.
CDC received response from 69 commenters on the draft recommendations
document. Public commenters included those from academia, professional
organizations, industry, and the public.
Many of the comments from the public were in support of the
recommendations. For those comments that proposed changes, the majority
related to removing the recommendation to screen for hepatitis C in
every pregnancy or removing the prevalence threshold for universal
screening. Feedback obtained during both the peer review process and
the public comment period was carefully reviewed and considered by CDC.
Ultimately no changes to the recommendation statement were made;
however, additional references and justification for the recommendation
to screen during every pregnancy and maintaining the prevalence
threshold were added to the document. A summary of public comments and
CDC's response is found in the Supporting Materials tab of the docket.
Dated: April 23, 2020.
Sandra Cashman,
Executive Secretary, Centers for Disease Control and Prevention.
[FR Doc. 2020-08960 Filed 4-27-20; 8:45 am]
BILLING CODE 4163-18-P
